Business Wire

IL-FOURKITES

6.3.2023 09:01:40 CET | Business Wire | Press release

Share
FourKites and Spotos Join Forces to Bring Real-time Supply Chain Visibility to European Shippers

Leading real-time supply chain visibility company FourKites today announced it will bring its network of end-to-end, real-time supply chain data to Spotos’ European customers. German-based Spotos offers a digital freight forwarding platform that gives shippers access to a wide network of carriers across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005078/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites and Spotos Join Forces to Bring Real-time Supply Chain Visibility to European Shippers (Graphic: Business Wire)

The partnership can give Spotos’ customers up-to-the-minute predictive estimated times of arrival (ETAs) and real-time status updates for their shipments at anytime, anywhere in Europe, whether in transit or at rest. With these advanced insights provided by FourKites, Spotos’ customers can reduce dwell and detention costs while optimising their network as shippers look to manage their costs better.

“Our mission is to revolutionise traditional freight exchange by enabling the best transparency, simplicity and accessibility for small and medium shippers,” said Šarūnas Stanislovėnas, founder and CEO of Spotos. “Now, thanks to FourKites' predictive insights, we will be able to provide our customers with ETAs that are more accurate and detailed than other available technologies could reliably deliver."

Spotos will also leverage FourKites’ carrier visibility platform, NIC-Place. This will give its customers access to granular data, including temperature tracking data for high-value transports, such as pharmaceuticals, fresh and frozen products, and electronic equipment throughout all parts of their fleet. With its proprietary Data Control Center (DCC), FourKites’ NIC-Place solution can provide a flexible and secure way for carriers to share supply chain data with customers, while giving them complete control of their business, their network and their data.

Based in Berlin, Spotos’ fully automated spot freight forwarding platform assures the highest-level service experience for small and medium-sized (SMB) shippers, regardless of their order volume or frequency. FourKites’ offering — powered by cutting-edge artificial intelligence and machine learning — will integrate with Spotos’ platform to extend visibility beyond transportation into yards, warehouses, stores and more.

Visibility across the entire supply chain network is crucial for SMB customers shipping high-value goods. By leveraging FourKites’ market-leading data network, Spotos’ customers can dynamically react to changes in plans and make more informed decisions in real time. In addition, FourKites will fuel insights that drive smarter operational planning and uncover new opportunities for operational efficiencies and cost savings.

“We’re delighted to team up with Spotos to ensure their customers can seamlessly track their freight in one unified platform,” said Marc Boileau, FourKites’ Senior Vice President of Sales, Network & Operations EMEA. “With FourKites, Spotos gets the most advanced tracking features for true end-to-end visibility, giving them a single pane of glass solution and the industry’s most accurate predictive ETAs for every shipment.”

“We’re excited about our partnership with FourKites,” continued Stanislovėnas. “FourKites has proven itself to be a true partner that has our best interests at heart and is always striving to do what’s right for our business and our customers.”

About FourKites

Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

About Spotos

Spotos revolutionised the old-school logistics industry, combining it with cutting-edge innovation, customer-oriented design, and a futuristic vision. It offers shippers access to a wide network of carriers across the EU region. The platform powertrain includes data science, artificial intelligence and machine learning.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005078/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye